Mirei Kamei
Oita University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mirei Kamei.
The Journal of Thoracic and Cardiovascular Surgery | 2011
Shin-ichi Yamashita; Keita Tokuishi; Kentaro Anami; Michiyo Miyawaki; Toshihiko Moroga; Mirei Kamei; Shuji Suehiro; Kiyoshi Ono; Shinsuke Takeno; Masao Chujo; Satoshi Yamamoto; Katsunobu Kawahara
OBJECTIVE The primary objective was to assess the feasibility and accuracy of intraoperative sentinel lymph node mapping by using a video-assisted thoracoscopic indocyanine green fluorescence imaging system in patients with clinical stage I non-small-cell lung cancer. METHODS Thirty-one patients who underwent operation between January 2009 and September 2009 were investigated for sentinel node biopsy. Indocyanine green fluorescence imaging was applied by an infrared light charge-coupled device, and sentinel nodes were identified intraoperatively and dissected. Histologic examination by hematoxylin-eosin staining was used to evaluate metastases. RESULTS Sentinel lymph nodes were identified by segmentectomy in 11 of 14 patients (78.5%) and by lobectomy in 14 of 17 patients (82.4%). The total identification rate was 80.7% (25/31 patients), the false-negative rate was 0% (0/24 patients), and the overall accuracy rate was 80.7% (25/31 patients). CONCLUSION Video-assisted thoracoscopic indocyanine green fluorescence image-guided surgery is feasible for sentinel node biopsy and may be a powerful tool to eliminate unnecessary lymph node dissection in patients with lung cancer.
Tumor Biology | 2011
Shin-ichi Yamashita; Keita Tokuishi; Takafumi Hashimoto; Toshihiko Moroga; Mirei Kamei; Kiyoshi Ono; Michiyo Miyawaki; Shinsuke Takeno; Masao Chujo; Satoshi Yamamoto; Katsunobu Kawahara
We investigated the possibility of human epididymis 4(HE4) to predict survival for patients with pulmonary adenocarcinoma. One hundred and thirty-seven patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis to determine the expression of HE4 and compared with the clinicopathological factors and survival. Serum levels of HE4 in lung adenocarcinoma were investigated by enzyme immunometric assay. Fifty-seven of 137 cases (41.6%) were HE4 positive. It was found that there was no correlation between HE4 expression by immunohistochemistry and clinicopathological factors, however, adenocarcinoma subtype was significantly associated with HE4 expression. Sera in lung adenocarcinoma were significantly higher than in healthy control. Five-year disease-free survival in the HE4-positive group (44.6%) was significantly different from that in the negative group (82.3%, p = 0.001) by immunohistochemistry. The five-year overall survival rate was 60.1% in the HE4-positive group, as compared with 90.8% in the HE4-negative group (p = 0.001). In multivariate Cox regression analysis, positive HE4 protein expression was a worse prognosis factor of disease-free and overall survival (HR = 3.7, 95%CI = [1.7–8.4], p = 0.001; HR = 5.5, 95%CI = [1.8–17.2], p = 0.003, respectively), in addition to nodal status as a powerful value. When HE4 expression in adenocarcinoma cases except the BAC were analyzed, nodal status and HE4 expression were independent prognostic factors in disease-free and overall survivals. These data showed that HE4 expression is associated with a worse prognosis and is a possible prognostic factor of lung adenocarcinoma.
European Journal of Cardio-Thoracic Surgery | 2009
Shinsuke Takeno; Shin-ichi Yamashita; Yoshiaki Takahashi; Kiyoshi Ono; Mirei Kamei; Toshihiko Moroga; Katsunobu Kawahara
PURPOSE The present study examined the clinicopathological impact of survivin expression in oesophageal squamous cell carcinoma (ESCC). In addition, the biological role of anti-apoptosis parameter in ESCC was examined immunohistochemically. PATIENTS AND METHOD Subjects comprised 71 patients followed up for 5 years after surgery for ESCC and analysed immunohistochemically to examine the clinicopathological impact of survivin expression. Separately, 37 fresh frozen samples of ESCC obtained recently were examined concerning splicing variant expression of survivin using reverse-transcription polymerase chain reaction (RT-PCR). RESULTS Immunohistochemical survivin expression was detected in the nuclei of 10 ESCC specimens (14.1%) and cytoplasm of 22 specimens (31.0%). Nuclear expression displayed no clinicopathological implications, but cytoplasmic expression correlated with histological differentiation (p=0.002) and tumour invasion (p=0.073) and showed prognostic impacts in univariate (p=0.0184) and multivariate (p=0.0299) analyses. Survivin, survivin-2B and survivin-deltaEx3 mRNA were amplified in 31 (83.8%), 23 (62.2%) and 26 (70.3%) specimens, respectively, by RT-PCR. Survivin-2B level related significantly with histological differentiation (p=0.038), but no other significant implication was identified between any mRNA and clinicopathological factors. CONCLUSION As a molecular biological anti-apoptotic factor, survivin expression was of use in assessing prognosis in ESCC. Inhibition of survivin may be useful as a molecular biological therapy in ESCC.
Hepato-gastroenterology | 2012
Shin-ichi Yamashita; Shinsuke Takeno; Moroga T; Mirei Kamei; Kiyoshi Ono; Yoshiaki Takahashi; Satoshi Yamamoto; Katsunobu Kawahara
Spontaneous rupture of the esophagus (Boerhaaves syndrome) is a critical disease. Most patients should undergo surgery for primary closure and drainage of the mediastinum and thorax. We treated a total of 7 cases of spontaneous rupture of the esophagus between December 2000 and August 2007. The time delay was 3 hours to 4 days (mean 16.7 hours) and the length of longitudinal tears ranged from 3 to 10cm (mean: 5.6cm). All cases underwent pedicled omental flap repair to reinforce the suture line. We introduced our technique by pedicled omental flap for successful treatment.
Digestive Endoscopy | 2009
Yoshiaki Takahashi; Shinsuke Takeno; Satoshi Watanabe; Mirei Kamei; Kiyoshi Ono; Shin-ichi Yamashita; Kenji Kashima; Katsunobu Kawahara
In patients with superficial esophageal cancer, especially in those with tumor invasion above the muscularis mucosae, lymph node metastasis is very rare. We report a case of superficial esophageal cancer who presented with lymph node metastasis. In another hospital a 49‐year‐old man was found to have a bulky tumor adjacent to the cardiac area of the stomach and a total gastrectomy was carried out. Postoperatively, the tumor was identified as a lymph node containing metastatic squamous cell carcinoma. The main lesion could not be identified on fluorodeoxyglucose positron emission tomography. On esophagogastric endoscopy, using the iodine spray technique, we found an unstained lesion about 32 cm from the incisor teeth. The tumor was removed using endoscopic mucosal resection. The entire resected specimen was examined histopathologically; the depth of the tumor was above the muscularis mucosae. Thirty‐four months after endoscopic mucosal resection, there is no sign of tumor recurrence or metastasis.
Surgical Case Reports | 2015
Mirei Kamei; Tsutomu Daa; Michiyo Miyawaki; Shuji Suehiro; Kenji Sugio
We herein report a case of adenomyoepithelioma (AME) of the breast with ductal carcinoma in situ (DCIS) involving a 71-year-old Japanese woman. She presented with bloody discharge from the left nipple. Mammography and ultrasonography showed a well-defined polygonal tumor. Fine-needle aspiration cytology of the mass and stamp cytology of the bloody nipple discharge showed malignancy. Mastectomy and a sentinel lymph node biopsy were performed. The final diagnosis was AME of the breast with DCIS. There are no reports of AME of the breast presenting with bloody nipple discharge; upon a diagnosis of AME of the breast with bloody nipple discharge, the possibility of the coexistence of breast cancer should thus be considered when encountering such cases.
Anticancer Research | 2007
Shin-ichi Yamashita; Yoshiko Masuda; Takashi Kurizaki; Yoshio Haga; Toshihiko Murayama; Satoshi Ikei; Mirei Kamei; Shinsuke Takeno; Katsunobu Kawahara
Anticancer Research | 2010
Mirei Kamei; Shin-ichi Yamashita; Keita Tokuishi; Takafumi Hashioto; Toshihiko Moroga; Shuji Suehiro; Kiyoshi Ono; Michiyo Miyawaki; Shinsuke Takeno; Satoshi Yamamoto; Katsunobu Kawahara
Breast Cancer | 2014
Shinsuke Takeno; Nobuyuki Kikuchi; Takashi Miura; Kentaro Anami; Yoshiaki Takahashi; Takafumi Hashimoto; Toshihiko Moroga; Shinichiro Akizuki; Mirei Kamei; Shuji Suehiro; Shin-ichi Yamashita; Katsunobu Kawahara
Hepato-gastroenterology | 2008
Shinsuke Takeno; Yoshiaki Takahashi; Satoshi Watanabe; Kiyoshi Ono; Mirei Kamei; Shin-ichi Yamashita; Katsunobu Kawahara